Lecifarma

What Lecifarma does

Lecifarma – Laboratório Farmacêutico is a privately held Portuguese pharmaceutical contract manufacturing organization (CMO) founded in 1985 and headquartered in Lousa, Portugal. The company operates GMP, HACCP, and HALAL-certified facilities and holds a medicinal cannabis license from INFARMED. It manufactures non-sterile pharmaceutical medications (solid forms: capsules, tablets, dragees, powders, lozenges; semi-solid forms: creams, gels, ointments, pastes; liquid forms: ampoules, vials, syrups, drops, oils), food supplements, cosmetics, and medical cannabis products (10% CBD oil and dry cannabis flower with 18-25% phytocannabinoid content). Its portfolio also includes complex therapeutic formulations such as LECIG (levodopa-entacapone-carbidopa intestinal gel for Parkinson's disease).

Lecifarma generates revenue primarily through B2B contract manufacturing fees, providing integrated services from formula conception and galenic development through stability studies, regulatory compliance, manufacturing, quality control, and packaging. Its secondary revenue stream is direct medicinal cannabis product sales for the Portuguese market and export through licensed distributors. The go-to-market is sales-led and consultative: direct engagement with pharmaceutical companies and distributors, supported by an active "Trabalhe connosco" hiring page. Customer acquisition relies on industry reputation, certifications, and referrals rather than paid marketing channels.

The company employs 51-100 staff and is undertaking a 1,300 m² facility expansion in 2025-2026 to scale capacity. It is a 100% Portuguese-capital-owned business with no disclosed external investors, parent company, or M&A activity. Distribution is global in scope via contract manufacturing relationships and export channels for cannabis products, though the core operational base is regional (Portugal).

Name

Lecifarma

Legal name

Lecifarma - Laboratório Farmacêutico

Website

https://lecifarma.pt

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

51–100 employees

Short description

Lecifarma is a privately held Portuguese pharmaceutical contract manufacturing organization (CMO) founded in 1985, serving pharmaceutical companies and distributors with GMP-certified production of medications, food supplements, cosmetics, and medicinal cannabis products across solid, semi-solid, and liquid dosage forms.

Ownership category

akta.pro rank

Headquarters

HQ city

Loures

HQ country

Portugal

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Contract Manufacturing Services: Large-scale contract manufacturing for third parties under GMP compliance. Lecifarma develops and manufactures pharmaceutical specialties, food supplements, and cosmetic products for other companies. Revenue generated through manufacturing fees and service contracts with pharmaceutical companies requiring production capacity.
2. Product Development Services: Integrated solution encompassing formula conception, galenic development studies, stability studies, and regulatory evaluation. They also support companies launching products with acquired technology, providing technical knowledge and specialized industrial infrastructure.
3. Medicinal Cannabis Products: Processing and packaging of cannabis-based products including CBD oils and dry cannabis flower for national market and export. Services include filling, analytical validation, stability testing, ACM process, and batch release.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Lecifarma is a Portuguese GMP-certified contract manufacturing laboratory that produces non-sterile pharmaceutical medications (solid, semi-solid, and liquid dosage forms), food supplements, cosmetics, and medicinal cannabis products for third-party clients. It also supports customers through formula conception, galenic development, stability studies, regulatory evaluation, and full-scale Contract Manufacturing (CMO) services, and develops its own specialty products such as LECIG intestinal gel and cannabis-based SKUs.

Product overview

Lecifarma is a Portuguese pharmaceutical laboratory offering an integrated portfolio of pharmaceutical products and services. The company manufactures non-sterile medications in solid (capsules, tablets, pills, dragees, granulates, powders, lozenges), semi-solid (creams, gels, lotions, pastes, ointments, unguents), and liquid forms (ampoules, vials, elixirs, emulsions, suspensions, solutions, syrups, drops, oils). Beyond pharmaceutical medications, the portfolio includes food supplements, cosmetics, and medical cannabis products (CBD oil 10% and dry cannabis flower 18-25% phytocannabinoids). The company also offers specialized services including medicinal cannabis processing (filling, extraction, and packaging), raw material handling, and contract manufacturing (GMP-certified). LECIG (levodopa-entacapone-carbidopa intestinal gel) is a therapeutic product for Parkinson's disease patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Contract Pharmaceutical Manufacturing (CMO) Services End-to-end GMP-certified contract manufacturing of pharmaceutical specialties, food supplements, cosmetics, and medical devices for pharmaceutical companies and brand owners that lack in-house production capacity or want to scale launches without capex.
• Medicinal Cannabis Processing Services INFARMED-licensed cannabis processing covering plant handling, decontamination, filling, analytical validation, stability testing, ACM process compliance, batch release, and oil extraction for distributors and brand owners.
• Óleo CBD 10% (10% CBD Oil) Proprietary 10% CBD oil product sold in 20ml amber glass bottle with graduated pipette for the Portuguese national market and export through licensed distributors.
• Flor Seca de Canábis (Dry Cannabis Flower) Proprietary dry cannabis flower SKU packaged in 10g HDPE bottles with 18-25% phytocannabinoid content, available for the Portuguese national market and export through licensed distributors.
• LECIG (Levodopa-Entacapone-Carbidopa Intestinal Gel) Proprietary intestinal gel formulation of levodopa, entacapone, and carbidopa for Parkinson's disease patients, used as an alternative therapeutic option after failure of subcutaneous foslevodopa/foscarbidopa therapy.

Quantifiable outcome

• Well-tolerated treatment outcomes in clinical settings (from independent study using Lecifarma product LECIG)

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Corden Pharma: European full-service CDMO covering APIs, drug products, and packaging with multiple EU GMP sites; competes for the same EU pharmaceutical outsourcing contracts.
• Recipharm: European CDMO offering contract development and manufacturing of pharmaceuticals across solid, semi-solid, and sterile forms; competes for the same mid-sized pharma outsourcing mandates as Lecifarma.
• Aenova: German-headquartered pharmaceutical contract manufacturer with broad solid and semi-solid dosage form capabilities; comparable scale and customer base to Lecifarma's pharma CMO offering.
• Siegfried: Swiss pharmaceutical CDMO with GMP-certified API and finished dose manufacturing across multiple dosage forms; overlaps directly with Lecifarma's CMO and formulation development services.
• Medochemie: Cyprus-based pharmaceutical manufacturer producing generics and providing contract manufacturing across multiple dosage forms; comparable CMO-style operations and EU market positioning.
• Famar: European pharmaceutical contract manufacturer providing sterile and non-sterile dosage form production across multiple sites; directly comparable in scale and service portfolio.
• Hovione: Portugal-based global CDMO specializing in drug substance and drug product manufacturing with deep formulation expertise; the closest geographic and operating-model peer to Lecifarma.

Broad incumbents

• Catalent: Large global CDMO with extensive drug product, biologics, and oral dose manufacturing; broader portfolio but directly competes with Lecifarma for European CMO contracts from mid-sized pharma clients.
• Jazz Pharmaceuticals (GW Pharmaceuticals): Holds the leading EU-approved cannabinoid medicine franchise (formerly GW Pharmaceuticals) and operates EU GMP cannabinoid manufacturing; a broader incumbent in the niche where Lecifarma's cannabis processing competes.

Emerging players

• Tilray Brands: Global cannabis company with EU GMP-certified cultivation and processing operations; competes in the same medicinal cannabis processing and finished product segment Lecifarma serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lecifarma